New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
14:40 EDTSLXP, AGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Sterne Agee said a potential Allergan acquisition of Salix (SLXP) would be accretive up to $190 per share.
News For SLXP;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:45 EDTSLXPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
March 25, 2015
12:58 EDTSLXPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
March 23, 2015
16:14 EDTAGNPershing Square liquidates stake in Allergan
Subscribe for More Information
09:03 EDTAGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
16:33 EDTSLXPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
10:18 EDTSLXPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
March 19, 2015
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:45 EDTSLXPSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information
March 17, 2015
09:13 EDTAGNActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:58 EDTAGNActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTAGNActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTAGNActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTAGNActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use